Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > ATE

<< Previous

Bullboard Posts

Next >>

Comment by rixpixon Aug 06, 2021 8:54am

226 Views

Post# 33662634

RE:ATE

The purchases are not really that convincing.
I was expecting a lot more shares to be bought.
Pretty much symbolic if not anything else.
Marcel sold 75K @ 4 buxx and only buys 12K now?
Not too re-assuring....

Pronorvista wrote: Filing
DateTransaction
DateInsider NameOwnership
TypeSecuritiesNature of transactionVolume or ValuePriceAug 5/21Aug 5/21Stauffer, JosephDirect OwnershipCommon Shares10 - Acquisition in the public market17,343$0.857
USDAug 5/21Aug 5/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market3,000$1.08
Aug 5/21Aug 5/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market7,000$1.06
Aug 5/21Aug 4/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market12,500$1.02
Aug 5/21Aug 4/21Wallace, John LawrenceDirect OwnershipCommon Shares10 - Acquisition in the public market10,300$1.04
Jul 15/21Jul 14/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market2,600$3.42
Jul 15/21Jul 13/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market4,000$3.57
Jul 4/21Jun 30/21Curtis, Scott WilsonDirect OwnershipCommon Shares10 - Acquisition in the public market3,500$3.71
Jul 4/21Jun 30/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Acquisition in the public market4,000$3.70
Jun 6/21Jun 3/21Legault, Daniel MarcelDirect OwnershipCommon Shares10 - Disposition in the public market-75,000$4.00